Ann: Investor Presentation, page-525

First 525 Last

Share
Profile

Follow
JB1975

2,039 Posts.

1179

18/06/24

23:56

Post #: 74379579
Share

Originally posted by Bazsa: ↑

First I ask holders here , what is the outcome for CYP if MSB gains approval or not? My view is that CYPs future lies in some ones success of getting something across the line. CYP would then be able to work in reproducing the product at much larger scale and cheaper. When someone has a good potency assay you should be able to tweak the process , possibly from original cell source and effectively match the product.

It seems that @truss20 may have missed some of the progress MSB have made over the last 4 years.

"Essentially, MSB were unable to get approval of Rem-L in paediatric Gvhd. This was/is due to the current clinical trial data being not being adequately controlled and related potency assays were not sufficiently related to the mechanism of action."

This would be a good summary of facts recorded in CRL 1
We have moved way past those dark times, as we had the first Type A meeting, the results, we had to fix the potency assays before progressing clinical trials. It was not a clinical hold as the FDA continued to allow us to use the cells on compassionate grounds. We know just over 70 adults had been given the treatment after CRL 1

More importantly is the outcomes of the COMPLETE RESPONSE of BLA 2 . We had some good outcomes, the FDA did not question efficacy of 001. It has been deemed successful and well controlled. Matching patients and then following them is actually better than a RCT because it takes into account current standard of care. To confirm this a statement was released by a very high US expert " the outcomes in children are compelling "

As all know we still got a CRL . The reason given. We ( FDA) can not be assured that current stock would be as same that was used in 001. More confirmation that 001 has been found good. Please provide more data to show that current stock is the same as used in 001. After the 2 type A meeting the FDA concluded that they could not approve due to what they considered lack of having a adequately standardised product SI points to the regulation. This is the opinion of the FDA.

So how well was the product standardised in 001?
Out of 11 lots used in 001 just 2 had minimal impact on results on entry level data from patients in 001 but wouldn't it be likely that without treatment those results would have been negative.

Could it be considered the product was standardised appropriately for a P3 trial, FDA may have even made a similar mistake to what JB has.

Next , why would SI miss represent statements from the FDA ?
Sue is keeping a eye on things. FDA may make public comment to counter false or misleading claims.

Expand

"FDA may have even made a similar mistake to what JB has"

What mistake?

CYP Price at posting: 30.5¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

BC8

Black Cat Syndicate one pour away from being rerated as producer

ASX Market Open: Australian stocks rise on US market strength, as inflation data points to a Fed cut in September

ABY

Adore Beauty appoints former David Jones exec as new CEO

NVA

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

ARU

Arafura updates gas supply agreement with Mereenie JV for 16.4PJ supply to Nolans REE play

There are more pages in this discussion • 85 more messages in this thread...

First 525 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 25.5¢		Change 0.000(0.00%)		Mkt cap ! $45.80M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	20209	25.0¢

Sellers (Offers)

Price($)	Vol.	No.
25.5¢	13900	2

View Market Depth

No.	Vol.	Price($)
1	20209	0.250
2	49573	0.245
2	102000	0.240
1	100000	0.235
2	15173	0.230

Price($)	Vol.	No.
0.255	13900	2
0.260	36715	1
0.265	8119	2
0.270	30000	1
0.290	1900	1

Last trade - 09.40am 29/07/2024 (20 minute delay)

CYP (ASX) Chart

Day chart unavailable

Ann: Investor Presentation, page-525

Black Cat Syndicate one pour away from being rerated as producer

ASX Market Open: Australian stocks rise on US market strength, as inflation data points to a Fed cut in September

Adore Beauty appoints former David Jones exec as new CEO

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Arafura updates gas supply agreement with Mereenie JV for 16.4PJ supply to Nolans REE play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor Presentation, page-525

Top Stories

Black Cat Syndicate one pour away from being rerated as producer

ASX Market Open: Australian stocks rise on US market strength, as inflation data points to a Fed cut in September

Adore Beauty appoints former David Jones exec as new CEO

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Arafura updates gas supply agreement with Mereenie JV for 16.4PJ supply to Nolans REE play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News